Brief: Liminal BioSciences Announces Discontinuation Of Fezagepras Development

Liminal BioSciences

21/07/2022 22:34

July 21 (Reuters) - Liminal BioSciences Inc  LMNL.O :
    * LIMINAL BIOSCIENCES ANNOUNCES DISCONTINUATION OF
FEZAGEPRAS
DEVELOPMENT
    * LIMINAL BIOSCIENCES INC- DECISION TO DISCONTINUE
DEVELOPMENT OF
FEZAGEPRAS IS BASED ON RESULTS FROM PHASE 1A SINGLE ASCENDING
DOSE ("SAD") CLINICAL TRIAL
    * LIMINAL BIOSCIENCES INC - RECOMMENDATION TO STOP
DEVELOPMENT
PROGRAM FOR FEZAGEPRAS WAS NOT BASED ON SAFETY CONCERNS
    * LIMINAL BIOSCIENCES INC- CONTINUE TO EXPLORE OTHER
DEVELOPMENT
OPPORTUNITIES TO ADD TO OUR PIPELINE
    * LIMINAL BIOSCIENCES INC - HAVE COME TO CONCLUSION EARLY IN
Q3 IN
LINE WITH PREVIOUSLY ISSUED GUIDANCE

Source text for Eikon:  ID:nCNWRWQHZa 
Further company coverage:  LMNL.O 

 ((Reuters.Briefs@thomsonreuters.com;))